Skip to content
The Chat Archive
sonar LMArena Search Arena 24K

give me the latest updates for bms

  1. User

    give me the latest updates for bms

  2. Assistant

    Here are the latest updates for Bristol Myers Squibb (BMS):

    1. Cost-Cutting and Strategic Reorganization:

      • BMS has announced an additional 2billionincost−cuttingmeasuresthrough2027,ontopofitsexistingprogramaimedatsaving2 billion in cost-cutting measures through 2027, on top of its existing program aimed at saving 1.5 billion by the end of 2025. This move is part of a broader effort to enhance operational efficiency and prepare for the loss of exclusivity for key drugs like Eliquis and Opdivo around 2028[1].
      • The company is focusing on becoming a "leaner, more efficient company" while investing in growth brands and promising scientific areas[1].
    2. Acquisitions and Pipeline Development:

      • BMS acquired Karuna Therapeutics at the end of 2023 for $14 billion, gaining access to Cobenfy, a treatment for schizophrenia. The company plans to conduct three Phase III trials for Cobenfy[1].
      • BMS is actively seeking deals or partnerships to strengthen its pipeline, particularly in core therapeutic areas where the science aligns with their strategic goals[1].
    3. Regulatory Approvals:

      • BMS received approval from the European Commission to expand the use of its CAR-T cell therapy, Breyanzi, for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy[3].
    4. Financial Performance:

      • In the fourth quarter of 2024, BMS reported 12.3billioninrevenue,an812.3 billion in revenue, an 8% increase from the previous year. The company expects 2025 revenue to be around 45.5 billion[1].
    5. Other Initiatives:

      • BMS has been recognized with the prestigious Prix Galien Award for its innovative contributions to healthcare[4].
      • The company is also involved in community initiatives, such as supporting patients with conditions like Hypertrophic Cardiomyopathy and psoriasis[4][5].

Responses were produced in different, uncontrolled contexts (system prompts, settings, prior turns). This is not a benchmark.

Identical first prompt